Veraprapas Kittipibul, Muthiah Vaduganathan, Uchechukwu Ikeaba, Karen Chiswell, Javed Butler, Adam D DeVore, Paul A Heidenreich, Joanna C Huang, Michelle M Kittleson, Karen E Joynt Maddox, Karthik K Linganathan, James J McDermott, Anjali Tiku Owens, Pamela N Peterson, Scott D Solomon, Orly Vardeny, Clyde W Yancy, Gregg C Fonarow, Stephen J Greene
BACKGROUND: Little is known regarding differences in cause-specific costs between heart failure (HF) with ejection fraction (EF) ≤40% vs >40%, and potential cost implications of sodium glucose co-transporter 2 inhibitor (SGLT2i) therapy. OBJECTIVES: This study sought to compare cause-specific health care costs following hospitalization for HF with EF ≤40% vs >40% and estimate the cost offset with implementation of SGLT2i therapy. METHODS: This study examined Medicare beneficiaries hospitalized for HF in the Get With The Guidelines-Heart Failure registry from 2016 to 2020...
April 6, 2024: JACC. Heart Failure